Want to see AU:VLS full AI Analyst Report?
VLS Stock Chart & Stats
AU$2.52
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.52
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$2.24 - AU$2.84
Previous CloseN/A
Volume18.65K
Average Volume (3M)14.76K
Market Cap
AU$151.15M
Enterprise ValueAU$106.82
Total Cash (Recent Filing)AU$33.70M
Total Debt (Recent Filing)AU$2.16M
Price to Earnings (P/E)13.8
Beta0.03
Next Earnings
Feb 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.83%
Share Statistics
EPS (TTM)0.20
Shares Outstanding54,371,357
10 Day Avg. Volume12,408
30 Day Avg. Volume14,758
Financial Highlights & Ratios
PEG Ratio0.72
Price to Book (P/B)2.57
Price to Sales (P/S)1.55
P/FCF Ratio9.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthRevenue has approximately doubled over five years, indicating durable product demand and expanding distribution. Continued growth across Australia and Asia can support operating scale, brand development and future earnings if the company maintains channel execution.
Conservative Balance SheetVery low leverage gives VLS financial flexibility to fund inventory, product development and market expansion without substantial interest burden. Meaningful equity compounding also strengthens resilience against demand volatility and external financing constraints.
High-Quality Cash GenerationCash flow broadly supporting reported profits improves earnings quality and provides internally generated funding for operations and growth. The strong 2025 rebound suggests the business can convert its expanding earnings into liquidity over time.
Bears Say
Margin CompressionLower profitability than earlier years suggests that costs, product mix or competitive pressures are absorbing part of the benefits from scale. Persistent compression could limit earnings growth even if revenue continues to expand.
Volatile Cash ConversionUneven conversion of earnings into cash can make funding needs and dividend capacity less predictable. Working-capital volatility may reflect inventory or receivables changes, creating execution risk as VLS expands across products and markets.
Declining Returns On CapitalLower returns on shareholder capital indicate that incremental assets or equity are generating somewhat less profit than in earlier periods. If this trend continues, expansion may become less efficient and place greater importance on margin improvement.
Vita Life Sciences Limited News
VLS FAQ
What was Vita Life Sciences Limited’s price range in the past 12 months?
Vita Life Sciences Limited lowest share price was AU$2.24 and its highest was AU$2.84 in the past 12 months.
What is Vita Life Sciences Limited’s market cap?
Vita Life Sciences Limited’s market cap is AU$151.15M.
When is Vita Life Sciences Limited’s upcoming earnings report date?
Vita Life Sciences Limited’s upcoming earnings report date is Feb 25, 2027 which is in 183 days.
How were Vita Life Sciences Limited’s earnings last quarter?
Vita Life Sciences Limited released its earnings results on Aug 17, 2026. The company reported AU$0.102 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Vita Life Sciences Limited overvalued?
According to Wall Street analysts Vita Life Sciences Limited’s price is currently Overvalued.
Does Vita Life Sciences Limited pay dividends?
Vita Life Sciences Limited pays a Semiannually dividend of AU$0.095 which represents an annual dividend yield of 4.83%. See more information on Vita Life Sciences Limited dividends here
What is Vita Life Sciences Limited’s EPS estimate?
Vita Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vita Life Sciences Limited have?
Vita Life Sciences Limited has 54,371,357 shares outstanding.
What happened to Vita Life Sciences Limited’s price movement after its last earnings report?
Vita Life Sciences Limited reported an EPS of AU$0.102 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.857%.
Which hedge fund is a major shareholder of Vita Life Sciences Limited?
Currently, no hedge funds are holding shares in AU:VLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vita Life Sciences Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:VLS Sentiment 100%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth AU$128.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.60%
12-Months-Change
Fundamentals
Return on Equity
4.83%
Trailing 12-Months
Asset Growth
7.80%
Trailing 12-Months
Company Description
Vita Life Sciences Limited
Vita Life Sciences Limited is an Australian healthcare company specializing in the formulation, packaging, distribution, and sale of vitamins and nutritional supplements. The company's reach spans Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. In addition to core supplements, their product range encompasses minerals, various herbs, and superfoods. They offer solutions targeting a broad spectrum of therapeutic areas, including nervous system support, general nutrition, immunity, hair, skin, and nails, liver and digestion, weight management, cardiovascular health, pain and inflammation, pregnancy and breastfeeding, and health specifically for men, women, and children. Products also provide antioxidant benefits and support for bones and joints. Marketed under their prominent brands—Herbs of Gold, VitaHealth, and VitaScience—these offerings are sold through pharmacies and health food channels. Established in 1947, Vita Life Sciences Limited is headquartered in Kirrawee, Australia.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Epsilon Healthcare Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―